Concurrent activation of RAS/ERK and PI3K/AKT pathways is implicated in prostate cancer progression. The negative regulators of these pathways, including sprouty2 (SPRY2), protein phosphatase 2A (PP2A), and phosphatase and tensin homolog (PTEN), are commonly inactivated in prostate cancer. The molecular basis of cooperation between these genetic alterations is unknown. Here, we show that
Rachana Patel ... Owen J. Sansom, Hing Y. Leung
SPRY2 KD decreases cell proliferation despite activation of mitogenic signaling.
Copyright © 2015 American Society for Clinical Investigation